HB4963, titled the Marijuana 1-to-3 Act of 2025, would require the Attorney General to reschedule marijuana from Schedule I to Schedule III under the federal Controlled Substances Act. The bill directs that this transfer occur by order within 60 days after enactment, and it defines marijuana by reference to the CSA term “marihuana.”
In practical terms, the bill would change marijuana’s federal status from a category reserved for substances deemed to have a high potential for abuse and no accepted medical use to a less restrictive category that recognizes accepted medical use and lower abuse potential relative to Schedule I substances. The measure does not itself create a broader regulatory framework, but it would alter how federal law treats marijuana and could affect enforcement, research, medical access, and tax treatment under federal law.
Impact
The bill would amend the operation of the Controlled Substances Act by mandating a specific rescheduling of marijuana from Schedule I to Schedule III, overriding the usual administrative scheduling process in sections 201 and 202. If enacted, it would directly affect federal drug classification and could have downstream effects on criminal enforcement, medical cannabis research, prescribing and dispensing rules, and business taxation issues tied to Schedule I status. It would not automatically legalize marijuana nationwide, but it would substantially reduce federal restrictions compared with its current classification.
Sentiment
The available context shows no recorded committee debate or votes, so there is no documented floor or committee sentiment in the materials provided. Based on the bill’s title and substance, it appears to be a pro-rescheduling measure intended to liberalize federal marijuana policy, but the legislative record here does not show formal support or opposition from members.
Contention
The central point of contention is the federal rescheduling of marijuana itself: supporters would likely view Schedule III status as a recognition of medical use and a step toward reduced federal barriers, while opponents may object to weakening federal drug controls or to bypassing the standard scheduling process. Another likely issue is the bill’s directive that the Attorney General act by order within 60 days, which could be seen as limiting agency discretion and accelerating a policy change that some lawmakers may prefer to leave to administrative review.